Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4584
Source ID: NCT02278913
Associated Drug: Basal Bolus (Glargine And Glulisine)
Title: Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Hyperglycemia|Diabetes
Interventions: DRUG: Basal Bolus (Glargine and Glulisine)|DRUG: Human Insulin
Outcome Measures: Primary: Glycemic control, The primary outcome of the study is to determine differences in glycemic control as measured by mean daily BG concentration between human insulin (NPH + Regular insulin) and basal bolus therapy (glargine once daily + glulisine), During hospitalization, an expected average of 10 days | Secondary: Hypoglycemia, Number of hypoglycemic events (\<70 mg/dl) and severe hypoglycemic events (\<40 mg/dl), During hospitalization, an expected average of 10 days|Insulin dose, Total daily dose of insulin, During hospitalization, an expected average of 10 days|Length of stay, Duration of hospitalization, During hospitalization, an expected average of 10 days|Mortality, Mortality is defined as death occurring during admission, During hospitalization, an expected average of 10 days
Sponsor/Collaborators: Sponsor: Universidad Nacional de Asunción
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 134
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2009-04
Completion Date: 2011-03
Results First Posted:
Last Update Posted: 2014-10-30
Locations: Clínica Médica del Hospital de Clínicas, Universidad Nacional de Asunción,, Asuncion, Paraguay
URL: https://clinicaltrials.gov/show/NCT02278913